SavedAdd your journal

Journals / Romatizma Dergisi / 2008 / Cilt: 23 - Sayı: 1

Oral ulcers caused by alendronate use

Alendronat kullanımına bağlı oral ülserler

Hakan CİNEMRE
Feyzi GÖKOSMANOĞLU
Necip Ö. AYTUĞ
Pages
35–37
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Most important possible adverse effects belong to gastrointestinal systems; esophagitis, gastric ulcers, dyspepsia, heartburn and rarely oral ulcers, osteonecrosis on jaws and esophagial stricturs are illustrated (Rheumatism 2008 23: 35-7)

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Bisphosphonates are the drugs which modulate bone turnover and reduce bone reabsorbsion.
📊
Key Findings & Data:Hence, they are used in postmenopausal osteoporosis , multiple myeloma or osteolisis associated with malign cancer.
💡
Conclusion & Impact:Most important possible adverse effects belong to gastrointestinal systems; esophagitis, gastric ulcers, dyspepsia, heartburn and rarely oral ulcers, osteonecrosis on jaws and esophagial stricturs are illustrated (Rheumatism 2008 23: 35-7)
🔬Design:Research Article
📍Scope:2008 Verileri
⚙️Variables:Yaşlı · 80 ve üzeri · Erkek

Abstract

Bisphosphonates are the drugs which modulate bone turnover and reduce bone reabsorbsion. Hence, they are used in postmenopausal osteoporosis , multiple myeloma or osteolisis associated with malign cancer. The rare complications are appearing more often now because of their wide use in treatments. Most important possible adverse effects belong to gastrointestinal systems; esophagitis, gastric ulcers, dyspepsia, heartburn and rarely oral ulcers, osteonecrosis on jaws and esophagial stricturs are illustrated (Rheumatism 2008 23: 35-7)

Özet

Bifosfonatlar kemik rezorpsiyonunu ve turnoverını azaltarak etki eden, bu nedenle postmenopozal osteoporoz, multipl myeloma ve maligniteye bağlı osteolizis gibi birçok kemik hastalığında kullanılan ajanlardır. Son yıllarda yaygın kullanımları ile nadir olan komplikasyonlarının görülme sıklığı artmıfltır. En sık gastrointestinal sisteme ait yan etkileri görülmekte olup özafajit, gastrik ülserler, dispepsi, retrosternal yanma nadiren de oral ülserler, çenede osteonekroz ve özafagial daralma bildirilen yan etkileridir. (Romatizma 2008; 23: 35-7)

🔖

Cite This Article

CİNEMRE, H., GÖKOSMANOĞLU, F., AYTUĞ, N. Ö. (2008). Oral ulcers caused by alendronate use. Romatizma Dergisi, Cilt: 23 - Sayı: 1, 35–37. https://ajindex.com/articles/305931

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Rodan GA, Reszka AA. Bisphosphonate mechanism of action. Curr Mol Med 2002; 2: 571-7
  2. Schmutz JL, Barbaud A, Trechot P. Alendronate and mouth ulcers: careful interrogation of the patient to start with. Ann Dermatol Venereol 2005,132: 930
  3. Fleish H. Bisphosphonates: mechanisms of action. Endocr Rev 1998; 19:80-100
  4. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonateinduced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005; 63: 1567-75
  5. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996; 334: 488-93
  6. Michigami T, Hiraga T, Williams PJ, Niewolna M, Nishimura R, Mundy GR et al. The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs. Breast Cancer Res Treat 2002; 75: 249-58
  7. Bauss F, Body JJ. Ibandronate in metastatic bone disease: a review of preclinical data. Anticancer Drugs 2005; 16: 107-8
  8. Malik AR, Campbell SH, Torna NM. Bilateral acute anterior uveitis after alendronate. Br J Ophthalmol 2002; 86: 1443
  9. Ghose K, Waterworth R, Trolove P, Highton J. Uveitis associated with pamidronate. Aust N Z J Med 1994; 24: 320
  10. Hernandez JL. Bifosfonatos intravenosos y osteoporosis. En: Riancho JA, Gonzalez J. Manual Prâctico de osteoporosis y enfermedades del metabolismo mineral. Madrid: Jarpyo Editores; 2004; p: 19
  11. Gonzâlez-Moles MA, Bagân-Sebastiân JV. Alendronate-related oral mucosa ulcerations. J Oral Pathol Med 2000; 29: 514-8
  12. Marx RE. Pamidronate (Aredia) and zolendronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61:1115-17.